Christian D. Fankhauser
@CDFankhauser
Followers
1K
Following
2K
Media
52
Statuses
483
Urologist, MPH Harvard school of Public health, EAU testis cancer guideline panel & YAU prostate cancer associate, ERAS cystectomy panel, SAKK GU core group
Luzern, Schweiz
Joined July 2020
It's out 🚀 Our multicentric collaboration just got published in @BJUIjournal. Huge thanks to all our incredible co-authors and the @YAUpenile_tesCa who made this work possible. Read it here: https://t.co/qJN56jRI4U
@MaartenAlbersen, @Brouwer_MD_PhD, @BE_Ayres, @CDFankhauser
bjui-journals.onlinelibrary.wiley.com
Objectives To assess local recurrence (LR) and its impact on cancer-specific survival (CSS) in an international multicentric homogeneous cohort of lower-risk patients with penile squamous cell...
0
5
11
New out in @TheLancetOncol with Ted Schaeffer: https://t.co/mdc6hQNpUN "Revisiting prostate cancer active surveillance candidacy" A close look at the fallacy and risks of active surveillance (AS) in unselected intermediate risk (IR) men. @wandering_gu @TylerSbrt
pubmed.ncbi.nlm.nih.gov
Revisiting prostate cancer active surveillance candidacy
2
19
67
Ever wondered whether elective scrotal surgery really needs perioperative antibiotic prophylaxis (PAP)? 🤔 Our new @wjurol study found a 3× lower SSI rate (12% vs 4%; p=0.058) and fewer readmissions (26% vs 16%; p=0.13) with PAP. Although not statistically significant, PAP may
1
2
3
Would surgery add survival benefit to the systemic treatment in patients with oligometastatic prostate cancer ? A new data highlights this; 👉Adding radical prostatectomy to best systemic therapy cut 5-yr cancer-specific mortality from 23% to 13% (HR 0.39, p=0.045). Early
0
46
127
Still leading the pack! @EUplatinum
European Urology remains at the top of our field in Nephrology and Urology! With the new IF of 25.2, over 2 million website downloads, and 40.7k followers on Twitter we are constantly striving to be a cut above the rest! Thank you to our Authors, Reviewers, and Readership!
0
2
9
@JoshMeeks provides an amazing overview of the significant data emerging in the BCG-unresponsive NMIBC space, focusing on the CIS cohorts. We also discuss the recent ODAC decision on UGN-102 for lower risk disease which was recently FDA approved. https://t.co/xMrAN0SxPk
1
30
77
It's #BladderCancerAwarenessMonth! Urologists play a key role in smoking cessation counseling. Tune in as @CDFankhauser and Dr. Richard Matulewicz @MSKCancerCenter discuss #URO54
https://t.co/vXXTpjhG7e
0
2
9
Thanks @Cacciamani_MD 🙏
⚡️ Use AI to boost your practice! This video covers 11 immediate applications, from AI scribes to virtual assistants Here's a bonus quote from @CanesDavid, an outstaying colleague and one of my source of inspiration.. (for real!!) "If you're entering patient information though,
0
1
9
New results from the CREST Study (NCT04165317) for HR-NMIBC: Adding sasanlimab to BCG induction + maintenance shows: •32% ⬇️of EFS event (HR 0.68, p=0.0095) •>50% reduction in HG recurrence •No difference in overall survival (OS interim HR 1.13, p=0.6791) #AUA25 #bladdercancer
2
25
64
More great data from Alberta: @urethrologist present long-term urinary toxicity following various tx combinations for #prostatecancer RP seems to do the best, but none of these curves flattens over time. #aua25
2
5
22
Nobel laureate Bill Kaelin on Killing the Science Golden Goose. "This is especially worrisome because becoming a scientist is largely taught by apprenticeship, with each generation teaching the next. We risk losing the next generation, our “seed corn”" https://t.co/MMaApyXXOe
9
48
167
Great topic and speaker
❓ Role of SBRT-only in hormone-sensitive oligometastatic prostate cancer ❓ Value of 6-months ADT added to SBRT ❓ Appropriate endpoints Virtual Grand Rounds in Radiation Oncology https://t.co/LnWKWLtxNz Proudly presenting: @BarbaraJereczek Wed April 2nd 17:00 – 17:30 CET 👇
1
0
4
Tired of the noise on @X? Join our @telegram channel w/all the key European Urology Network updates and important #urology pubs in one place. No Elon musk tweets or ads just pubs and your own community. Subscribe info below 👇 @Uroweb @AmerUrological #AcademicResearch
0
3
19
Rethinking Post-Chemo Surgery in NSGCT: 🔘Mass size alone isn’t enough to decide on RPLND after chemotherapy. 🔘Teratoma or yolk sac tumor in orchiectomy significantly raises the risk of residual disease. @Annals_Oncology @tompowles1 @myESMO @Uroweb @OncoAlert
0
29
55
💫🌟New Review on Testicular Germ Cell Tumors! 🌟💫 @nirmishsingla @AdityaBagrodia Dr #EzraBaraban @yalepathology @CDFankhauser @yasserged @JAMA_current @OncoAlert 💡 Key Insights: 🧬 Epidemiology & Risk Factors 🔹 Most common solid malignancy in men aged 15-40 🔹 ~10,000 cases
1
76
167
Could implementing Entrustable Professional Activities (EPAs) enhance training conditions and integrate modern didactic concepts? Explore our latest publication on this topic: https://t.co/YtM6KQINZx Thank you @SAKK_ch , @CDFankhauser and the whole team of the @KantonsspitalLU!
0
1
1
A true privilege to work with incredible co-authors @nirmishsingla @CDFankhauser @yasserged #ezrabaraban on this review. Thx to outstanding @JAMA_current editorial team! @UCSD_Urology @UCSDCancer @UCSDHealth @DrRanaMcKay @MadamSurgeonMD @cjkane10 @endourologyucsd
Testicular cancer is the most common solid malignancy in young men in the US. This Review summarizes current evidence regarding risk factors, diagnosis, and treatment of testicular cancer, particularly germ cell tumors, in adults and adolescents. https://t.co/qDuhaz89Xk
0
5
25
Testicular cancer is the most common solid malignancy in young men in the US. This Review summarizes current evidence regarding risk factors, diagnosis, and treatment of testicular cancer, particularly germ cell tumors, in adults and adolescents. https://t.co/qDuhaz89Xk
1
48
160
When control patients drop out for better options, outcomes get skewed=perceived inferiority bias In #BladderCancer trials this bias inflated PFS/OS for chemo + IO. Adjustments 🛑erased OS (nivolumab, CheckMate901) & PFS (pembrolizumab, KEYNOTE-361). RCT are not perfect
9
30
93